⚡ LIVE PULSE   

The Ophthalmic Milestone: FDA Approves Brytly, the First Non-Prescription Apraclonidine Drop for Eye Redness

FDA Approves Brytly, the First Non-Prescription Apraclonidine Drop for Eye Redness

The Ophthalmic Milestone: FDA Approves Brytly, the First Non-Prescription Apraclonidine Drop for Eye Redness

The Organ-Sparing Miracle and the Hepatic Cost: Analyzing Dostarlimab’s FDA Accelerated Approval for Rectal Cancer

The Organ-Sparing Miracle and the Hepatic Cost: Analyzing Dostarlimab’s FDA Accelerated Approval for Rectal Cancer

The Organ-Sparing Miracle and the Hepatic Cost: Analyzing Dostarlimab’s FDA Accelerated Approval for Rectal Cancer

A Paradigm Shift in Pediatric Diabetes: FDA Approves Awiqli as the First Once-Weekly Basal Insulin for Children

FDA Approves Awiqli as the First Once-Weekly Basal Insulin for Children

A Paradigm Shift in Pediatric Diabetes: FDA Approves Awiqli as the First Once-Weekly Basal Insulin for Children